Business
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L settingManageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxisLyell managem
About this update from Lyell Immunopharma, Inc.
[{"type":"image","alt":"Lyell Immunopharma, Inc","displaySize":"","headline":null,"caption":"Lyell Immunopharma, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":222,"url":"https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gyyLnTdzLBmCtbGQjs4MFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d","width":300,"height":222}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L setting","length":162,"tagName":"p"}]},{"val":[{"type":"text","content":"Manageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxis","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, Associate Professor at the David Geffen School of Medicine, University of California, Los Angeles, at 8:30 AM ET on Monday, December 8th","length":254,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":741,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced new clinical and translational data from the ongoing clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) in patients with large B-cell lymphoma (LBCL), which were presented today in two oral presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. As of the data cutoff date of September 5, 2025, ronde-cel continued to demonstrate robust clinical responses with a manageable safety profile appropriate for outpatie...